O'Shaughnessy Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

O'Shaughnessy Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.9M	Sell	42,063 -19,804	-32%	-$8.78M	0.1%	217
2026 Q1	$27.6M	Buy	61,867 +14,622	+31%	+$6.82M	0.14%	158
2025 Q4	$21.4M	Buy	47,245 +11,564	+32%	+$4.98M	0.12%	193
2025 Q3	$14M	Buy	35,681 +1,422	+4%	+$594K	0.08%	268
2025 Q2	$15.3M	Sell	34,259 -1,341	-4%	-$618K	0.1%	225
2025 Q1	$17.3M	Buy	35,600 +6,446	+22%	+$3M	0.14%	171
2024 Q4	$11.7M	Buy	29,154 +472	+2%	+$219K	0.1%	211
2024 Q3	$13.9M	Buy	28,682 +4,287	+18%	+$2.06M	0.12%	184
2024 Q2	$11.4M	Buy	24,395 +4,697	+24%	+$2.04M	0.12%	190
2024 Q1	$8.23M	Buy	19,698 +3,629	+23%	+$1.53M	0.09%	256
2023 Q4	$6.54M	Buy	16,069 +2,761	+21%	+$1.02M	0.09%	260
2023 Q3	$4.63M	Buy	13,308 +3,246	+32%	+$1.14M	0.07%	300
2023 Q2	$3.54M	Buy	10,062 +2,296	+30%	+$774K	0.05%	336
2023 Q1	$2.45M	Sell	7,766 -710	-8%	-$213K	0.04%	405
2022 Q4	$2.45M	Buy	8,476 +490	+6%	+$149K	0.04%	389
2022 Q3	$2.31M	Buy	7,986 +2,524	+46%	+$726K	0.04%	371
2022 Q2	$1.54M	Buy	5,462 +2,239	+69%	+$599K	0.03%	443
2022 Q1	$841K	Buy	3,223 +1,722	+115%	+$409K	0.01%	573
2021 Q4	$330K	Buy	1,501 +498	+50%	+$96.8K	0.01%	834
2021 Q3	$182K	Buy	1,003 +78	+8%	+$15.2K	﹤0.01%	1089
2021 Q2	$187K	Sell	925 -396	-30%	-$82.8K	﹤0.01%	1061
2021 Q1	$284K	Sell	1,321 -416	-24%	-$91.4K	0.01%	793
2020 Q4	$411K	Sell	1,737 -382	-18%	-$87.6K	0.01%	577
2020 Q3	$577K	Buy	2,119 +305	+17%	+$84.1K	0.02%	415
2020 Q2	$527K	Buy	1,814 +1,559	+611%	+$423K	0.02%	389
2020 Q1	$61K	Sell	255 -239	-48%	-$54.8K	﹤0.01%	738
2019 Q4	$108K	Buy	494 +493	+49,300%	+$99.8K	﹤0.01%	776
2019 Q3	$0	Hold	1	–	–	﹤0.01%	1263
2019 Q2	$0	Buy	+1	New	+$175	﹤0.01%	1232

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

O'Shaughnessy Asset Management's VRTX Position: Q2 2026 in Review

O'Shaughnessy Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 32% in Q2 2026, selling an estimated $8.78M and leaving 42,063 shares worth $20.9M. The position accounts for 0.1% of the portfolio, ranked #217.

O'Shaughnessy Asset Management first reported a position in VRTX in Q2 2019 and has held it in 29 quarters since. The position peaked at $27.6M in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

O'Shaughnessy Asset Management held 42,063 shares of Vertex Pharmaceuticals worth $20.9M as of Q2 2026.
O'Shaughnessy Asset Management sold 19,804 Vertex Pharmaceuticals shares in Q2 2026, an estimated $8.78M.
Vertex Pharmaceuticals made up 0.1% of O'Shaughnessy Asset Management's portfolio in Q2 2026, its #217 holding.
O'Shaughnessy Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
O'Shaughnessy Asset Management's Vertex Pharmaceuticals position peaked at $27.6M in Q1 2026.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.